The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its ...

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

What Pfizer’s recent performance tells you right now Pfizer (PFE) has drawn fresh attention after a period in which the share ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

Pfizer made one thing clear this week: It's officially back in the obesity race.